FDA Oncology Announcements

Anti-PD-L1 × Thoracic × Clear all

10 Announcements

FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer

Trial: IMforte
Drugs: Zepzelca (lurbinectedin) · Alkylating agent, Tecentriq (atezolizumab) · Anti-PD-L1 antibody, Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves durvalumab for limited-stage small cell lung cancer

Trial: ADRIATIC
Drug: Imfinzi (durvalumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer

Trial: AEGEAN
Drug: Imfinzi (durvalumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer

Trial: POSEIDON
Drugs: Imjudo (tremelimumab) · Anti-CTLA-4 antibody, Imfinzi (durvalumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer

Drug: Tecentriq (atezolizumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression

Drug: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves durvalumab for extensive-stage small cell lung cancer

Trial: CASPIAN
Drugs: IMFINZI (durvalumab) · Anti-PD-L1 antibody, etoposide · Topoisomerase II inhibitor
Condition: Thoracic

FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations

Trial: IMpower130
Drugs: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody, paclitaxel protein-bound · Taxane, carboplatin · Platinum agent
Condition: Thoracic

FDA approves atezolizumab for extensive-stage small cell lung cancer

Trial: IMpower133
Drugs: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody, carboplatin · Platinum agent, etoposide · Topoisomerase II inhibitor
Condition: Thoracic

FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC

Trial: PACIFIC
Drug: Imfinzi (durvalumab) · Anti-PD-L1 antibody
Condition: Thoracic